Skip to content

TEVA PHARMACEUTICAL INDUSTRIES LIMITED: filings

Every TEVA PHARMACEUTICAL INDUSTRIES LIMITED annual and quarterly report in the SEC record with the published financial measures it tagged, 43 filings, each linked to its SEC index.

Filings with published measures

Each page shows what one filing reported, as tagged in that filing, with the periods it covered. Later filings can restate a value; the company overview shows the latest-filed value per period.

FormFiledFiscal periodMeasuresFactsSEC accession
10-Q2026-07-29fiscal Q2 2026381230001193125-26-323619
10-Q2026-04-29fiscal Q1 202638810001193125-26-191513
10-K2026-02-03fiscal FY 2025471240001193125-26-034532
10-Q2025-11-05fiscal Q3 2025371180001193125-25-266895
10-Q2025-07-30fiscal Q2 2025371180001193125-25-169296
10-Q2025-05-07fiscal Q1 202537780001193125-25-114889
10-K2025-02-05fiscal FY 2024491310001193125-25-020826
10-Q2024-11-06fiscal Q3 2024371240001193125-24-252039
10-Q2024-07-31fiscal Q2 2024371240001193125-24-189924
10-Q2024-05-08fiscal Q1 202437800001193125-24-134200
10-K2024-02-12fiscal FY 2023481890001193125-24-031005
10-Q2023-11-09fiscal Q3 2023371190001193125-23-274495
10-Q2023-08-02fiscal Q2 2023381230001193125-23-201707
10-Q2023-05-10fiscal Q1 202338810001193125-23-140697
10-K2023-02-10fiscal FY 2022501320001193125-23-031250
10-Q2022-11-03fiscal Q3 2022391120001193125-22-276883
10-Q2022-07-27fiscal Q2 2022391120001193125-22-203392
10-Q2022-05-03fiscal Q1 202239820001193125-22-138669
10-K2022-02-09fiscal FY 2021501320001193125-22-032667
10-Q2021-10-27fiscal Q3 2021381100001193125-21-308672
10-Q2021-07-28fiscal Q2 2021381100001193125-21-227389
10-Q2021-04-28fiscal Q1 202138800001193125-21-136842
10-K2021-02-10fiscal FY 2020501880001193125-21-036239
10-Q2020-11-05fiscal Q3 2020381100001193125-20-286828
10-Q2020-08-05fiscal Q2 2020381100001193125-20-210627
10-Q2020-05-07fiscal Q1 202039820001193125-20-136212
10-K2020-02-21fiscal FY 2019511870001193125-20-044221
10-Q2019-11-07fiscal Q3 2019441200001193125-19-287265
10-Q2019-08-07fiscal Q2 2019441200001193125-19-215317
10-Q2019-05-02fiscal Q1 201944880001193125-19-134970
10-K2019-02-19fiscal FY 2018491860001193125-19-043564
10-Q2018-11-01fiscal Q3 2018411140001193125-18-315734
10-Q2018-08-02fiscal Q2 2018401090001193125-18-236536
10-Q2018-05-03fiscal Q1 201838760001193125-18-150803
10-K2018-02-12fiscal Q4 2017471520001193125-18-039076
20-F2017-02-15fiscal Q4 2016481330001193125-17-045463
20-F2016-02-11fiscal Q4 2015481280001193125-16-459785
20-F2015-02-09fiscal Q4 2014461270001193125-15-039151
20-F2014-02-10fiscal FY 2013461280001193125-14-041871
20-F2013-02-12fiscal FY 2012441180001193125-13-050510
20-F2012-02-17fiscal FY 2011431140001193125-12-067417
20-F2011-02-15fiscal FY 2010441160001193125-11-036753
20-F2010-02-22fiscal FY 2009381000001193125-10-036435

Inspect the source

Entity
TEVA PHARMACEUTICAL INDUSTRIES LIMITED / CIK 0000818686
Captured
2026-09-19T15:07:07.385Z
SEC response SHA-256
f2c93c1e5a25cb18cb0b293c07294b344882e3789d9edd47f98fdd8c904c6c6d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000818686.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))